دورية أكاديمية
أعرض في EDS

Biomarkers-based personalized follow-up in chronic heart failure improves patient's outcomes and reduces care associate cost.

التفاصيل البيبلوغرافية
العنوان: Biomarkers-based personalized follow-up in chronic heart failure improves patient's outcomes and reduces care associate cost.
المؤلفون: Leon-Justel A; Macarena University Hospital, Dr. Fedriani nº3, 41009, Seville, Spain. antonio.leonj.sspa@juntadeandalucia.es., Morgado Garcia-Polavieja JI; Juan Ramon Jimenez University Hospital, Huelva, Spain., Alvarez-Rios AI; Virgen del Rocio University Hospital, Seville, Spain., Caro Fernandez FJ; Juan Ramon Jimenez University Hospital, Huelva, Spain., Merino PAP; Juan Ramon Jimenez University Hospital, Huelva, Spain., Galvez Rios E; Juan Ramon Jimenez University Hospital, Huelva, Spain., Vazquez-Rico I; Juan Ramon Jimenez University Hospital, Huelva, Spain., Diaz Fernandez JF; Juan Ramon Jimenez University Hospital, Huelva, Spain.
المصدر: Health and quality of life outcomes [Health Qual Life Outcomes] 2021 May 08; Vol. 19 (1), pp. 142. Date of Electronic Publication: 2021 May 08.
نوع المنشور: Comparative Study; Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101153626 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7525 (Electronic) Linking ISSN: 14777525 NLM ISO Abbreviation: Health Qual Life Outcomes Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central, c2003-
مواضيع طبية MeSH: Ventricular Function, Left*, Biomarkers/*analysis , Health Care Costs/*statistics & numerical data , Heart Failure/*economics , Heart Failure/*therapy , Hospitalization/*economics , Quality of Life/*psychology, Aged ; Chronic Disease/economics ; Chronic Disease/therapy ; Cohort Studies ; Female ; Follow-Up Studies ; Hospitalization/statistics & numerical data ; Humans ; Male ; Middle Aged ; Predictive Value of Tests ; Spain
مستخلص: Background: Heart failure (HF) is a major and growing medical and economic problem, with high prevalence and incidence rates worldwide. Cardiac Biomarker is emerging as a novel tool for improving management of patients with HF with a reduced left ventricular ejection fraction (HFrEF).
Methods: This is a before and after interventional study, that assesses the impact of a personalized follow-up procedure for HF on patient's outcomes and care associated cost, based on a clinical model of risk stratification and personalized management according to that risk. A total of 192 patients were enrolled and studied before the intervention and again after the intervention. The primary objective was the rate of readmissions, due to a HF. Secondary outcome compared the rate of ED visits and quality of life improvement assessed by the number of patients who had reduced NYHA score. A cost-analysis was also performed on these data.
Results: Admission rates significantly decreased by 19.8% after the intervention (from 30.2 to 10.4), the total hospital admissions were reduced by 32 (from 78 to 46) and the total length of stay was reduced by 7 days (from 15 to 9 days). The rate of ED visits was reduced by 44% (from 64 to 20). Thirty-one percent of patients had an improved functional class score after the intervention, whereas only 7.8% got worse. The overall cost saving associated with the intervention was € 72,769 per patient (from € 201,189 to € 128,420) and €139,717.65 for the whole group over 1 year.
Conclusions: A personalized follow-up of HF patients led to important outcome benefits and resulted in cost savings, mainly due to the reduction of patient hospitalization readmissions and a significant reduction of care-associated costs, suggesting that greater attention should be given to this high-risk cohort to minimize the risk of hospitalization readmissions.
References: JAMA. 2013 Jul 3;310(1):66-74. (PMID: 23821090)
J Clin Med. 2019 Dec 06;8(12):. (PMID: 31817815)
Eur J Prev Cardiol. 2020 Apr;27(6):622-632. (PMID: 31487998)
Am Heart J. 2005 Feb;149(2):209-16. (PMID: 15846257)
Am Heart J. 2014 Dec;168(6):901-8.e1. (PMID: 25458654)
Heart Lung. 2002 Jul-Aug;31(4):262-70. (PMID: 12122390)
BMC Cardiovasc Disord. 2018 May 2;18(1):74. (PMID: 29716540)
JAMA. 2017 Aug 22;318(8):713-720. (PMID: 28829876)
Circulation. 2010 Nov 9;122(19):1975-96. (PMID: 20937981)
Rev Esp Cardiol (Engl Ed). 2015 Jan;68(1):80-1. (PMID: 25440177)
Circulation. 2014 Jan 21;129(3):399-410. (PMID: 24446411)
Card Fail Rev. 2017 Apr;3(1):7-11. (PMID: 28785469)
Int J Cardiol. 2016 Jun 1;212:1-10. (PMID: 27015641)
PLoS One. 2014 Jan 15;9(1):e85466. (PMID: 24454874)
J Am Coll Cardiol. 2004 Aug 18;44(4):810-9. (PMID: 15312864)
Eur Heart J. 2014 Jun 14;35(23):1559-67. (PMID: 24603309)
Circulation. 2018 May 15;137(20):2101-2103. (PMID: 29760224)
Eur Heart J. 2016 Jul 14;37(27):2129-2200. (PMID: 27206819)
J Card Fail. 2010 Feb;16(2):150-6. (PMID: 20142027)
J Am Heart Assoc. 2019 Jul 2;8(13):e012272. (PMID: 31240976)
Eur Heart J. 2002 Dec;23(23):1861-6. (PMID: 12445535)
Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. (PMID: 17999842)
Eur Heart J. 2002 Jan;23(2):139-46. (PMID: 11785996)
Heart. 2000 May;83(5):596-602. (PMID: 10768918)
ESC Heart Fail. 2020 Feb;7(1):130-137. (PMID: 31916416)
J Cardiopulm Rehabil Prev. 2010 Mar-Apr;30(2):101-5. (PMID: 19952769)
Heart. 2002 Mar;87(3):235-41. (PMID: 11847161)
Heart Fail Rev. 2016 Jan;21(1):49-63. (PMID: 26572543)
JAMA Cardiol. 2018 Jan 1;3(1):44-53. (PMID: 29128869)
JACC Heart Fail. 2013 Feb;1(1):64-71. (PMID: 24621800)
Eur J Heart Fail. 2016 Jun;18(6):613-25. (PMID: 27324686)
J Am Coll Cardiol. 2018 Jan 16;71(2):201-230. (PMID: 29277252)
Circ Heart Fail. 2015 Mar;8(2):384-409. (PMID: 25604605)
Clin Chem. 2007 Apr;53(4):545-6. (PMID: 17384002)
Heart. 2007 Sep;93(9):1137-46. (PMID: 17699180)
Pharmacoeconomics. 2008;26(6):447-62. (PMID: 18489197)
فهرسة مساهمة: Keywords: Biomarkers; Budget impact; Heart failure; Patient outcomes; Patient value; Personalized medicine
المشرفين على المادة: 0 (Biomarkers)
تواريخ الأحداث: Date Created: 20210509 Date Completed: 20210614 Latest Revision: 20240402
رمز التحديث: 20240402
مُعرف محوري في PubMed: PMC8106851
DOI: 10.1186/s12955-021-01779-9
PMID: 33964944
قاعدة البيانات: MEDLINE
الوصف
تدمد:1477-7525
DOI:10.1186/s12955-021-01779-9